Syndax Pharmaceuticals SNDX Free cash flow
Discontinued — last reported Q4 '25
Free cash flow at other companies
Other financials
Where this comes from
Calculated from Syndax Pharmaceuticals’s reported figures.
The official record: Syndax Pharmaceuticals’s 10-K, filed February 26, 2026, on SEC EDGAR. View the filing →
Ask your AI about Syndax Pharmaceuticals's free cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Syndax Pharmaceuticals's free cash flow?
- Syndax Pharmaceuticals (SNDX) reported free cash flow of -$80.79M in Q4 2025.
- How has Syndax Pharmaceuticals's free cash flow changed year-over-year?
- Syndax Pharmaceuticals's free cash flow decreased by 17.6% year-over-year, from -$68.73M to -$80.79M.
- What is the long-term trend for Syndax Pharmaceuticals's free cash flow?
- Over 4 years (2021 to 2025), Syndax Pharmaceuticals's free cash flow has grown at a 82.7% compound annual growth rate (CAGR), from $29M to -$323.17M.
- What does free cash flow mean?
- Free cash flow represents the cash generated by a company after accounting for cash outflows to support operations and maintain or expand its capital asset base. It serves as a critical indicator of a company's ability to fund organic growth, pay down debt, or return capital to shareholders without relying on external financing.